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Contact: Jon “Tony” Rudbach, UM assistant vice president for research and economic
development, (406) 243-6670, triltd@aol.com.
UM BREAKTHROUGH STANDS THE TEST OF TIME
MISSOULA—
Most researchers dream of producing something that benefits humankind. University of
Montana scientist Jon “Tony” Rudbach did just that in 1976.
Rudbach is now U M ’s assistant vice president for research and economic development,
but back then he led a team of scientists in the U niversity’s Department of Microbiology. His
laboratory at that time was asked by the U.S. Food and Drug Administration to create a new
substance —or reagent —to test an innovative chemical that protects vaccines, drugs and other
injected substances from dangerous endotoxin.
“We received an $18,000 grant, which was a lot of money in those days,” Rudbach
said. “Since the reagent we produced became the international standard, I think it was money
well spent.”
Endotoxin is all around and inside us. It is a potent toxin created by the breakdown of
bacteria cell walls. Human beings can ingest endotoxin without symptoms, but if even
microscopic amounts get beyond our digestive tracts into other parts of our bodies, the results
can be fever, low blood pressure, shock, organ failure and death. Boiling or cooking can
destroy bacteria but not endotoxin.
Drug companies and hospitals once tested for the presence of endotoxin contaminates
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by injecting samples into rabbits. If the rabbits got a fever or died, the drug was discarded.
Then researchers at the Woods Hole Oceanographic Institute in Massachusetts
discovered that the sapphire-blue blood of horseshoe crabs contains a chemical called Limulus
Amebocyte Lysate (LAL), which clots in the presence of endotoxin. The compound is a
thousand times more effective at detecting the toxin than rabbit testing.
Once considered junk fish, horseshoe crabs now have blood that’s precious as gold,
since the compound inside these living fossils is found nowhere else on Earth. Science still
hasn’t figured out a way to make synthetic LAL.
But how do you test the potency and effectiveness of LAL? That’s where Rudbach
came in. His Montana lab tested LAL with endotoxin generated from a variety of bacteria.
This resulted in the discovery of a “typical” endotoxin with average biological potency —not
the most toxic or least toxic. This average endotoxin, which has excellent properties of
stability and solubility, was produced from Escherichia coli, though at least 16 other types of
bacteria also were tested during the UM research.
Rudbach said the standard endotoxin they produced looks like a white powder. People
could eat the stuff, but if it was injected, they wouldn’t last long. But it was perfect for testing
life-saving LAL supplies around the world, and the UM-created endotoxin became the standard
for testing the miracle horseshoe crab compound. It also established a set sensitivity for LAL
stocks around the globe, and the standard endotoxin remains stable for decades under normal
storage conditions.
“We developed the standard,” Rudbach said. “The reagent we designed is still in use
today.”
-more-
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The FDA has required an LAL test for all drugs used by humans since 1987, and UM ’s
endotoxin standard went international in 1997 when it was adopted by the World Health
Organization.
LAL is used to find contaminants in every injected drug and vaccine, every artificial
joint and implanted device, and every intravenous drip in every hospital in America, as well as
in many health-care facilities worldwide. Blood supplies generally aren’t tested by LAL, but
almost anything else injected or placed in the human body must pass muster with the chemical.
Thomas Novitsky is president and CEO of Associates of Cape Cod Inc. of
Massachusetts - one of the world’s leading LAL producers. He said, “It is a tremendous credit
to Tony that his standard has withstood the test of time and is still in use today. I have been
extremely fortunate in my career to have personally known most of the major players in
modern endotoxin research. Tony is definitely one of these.”
Rudbach said developing the standard endotoxin for the LAL test was an exciting time
in Missoula. The 8-member team in his lab included graduate and undergraduate students who
made important contributions to the research — students who later went on to successful
careers in a variety of fields.
Rudbach’s UM success catapulted him to the head of Infectious Disease and
Immunology Research at Abbott Laboratories in Illinois from 1982-85. He also taught at
Chicago Medical School before working as an administrator at Ribi ImmunoChem Research
Inc. in Hamilton from 1985 to 1995. During that time he also returned to UM as an adjunct
professor of microbiology and formed his own consulting firm, Technology Resources
International. He also was an officer for six years in the International Endotoxin Society.
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In his recent position as UM assistant vice president for research and economic
development, Rudbach works to stimulate Montana’s economy by transforming UM research
into private-sector business —a process called technology transfer.
It’s a role he relishes because one never knows when the fruits of Montana university
research will cast far greater shadows than those of the surrounding Rocky Mountains.
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